{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Lowest dose of alemtuzumab associated with transplant-related mortality at day 180","groups":[{"description":"Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant.\n\nalemtuzumab\n\nbusulfan\n\ncyclophosphamide\n\nmethotrexate\n\ntacrolimus\n\nallogeneic hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation","id":"OG000","title":"Alemtuzumab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to day 180","title":"Lowest Dose of Alemtuzumab Associated With Transplant-related Mortality","type":"PRIMARY","unitOfMeasure":"mg total dose"}